Citations

Clear

38 citation(s) found for "Craig, David".

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dingli, David , Cornell, Robert F. , Huff, Carol Ann , Bhutani, Divaya , Zonder, Jeffrey A. , Cole, Craig E. , Vij, Ravi , Abonour, Rafat , Schiller, Gary J. , Parker, Terri L., Costa, Luciano J. , Kaminetzky, David , Hoffman, James E. , Chari, Ajai , Wier, Scott Van, Ahmann, Gregory , Lopez, Ilsel, Kauffman, Michael , Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla, Choe-Juliak, Cassandra, Stewart, A. Keith, Vogl, Dan T. , Cornell, Robert Frank, Zonder, Jeffrey, Nooka, Ajay, Richter, Joshua , Cole, Craig, Schiller, Gary, Yee, Andrew J. , Van Wier, Scott, Picklesimer, Carla D, Chari, Ajai , Dingli, David , Bhutani, Divaya , Costa, Luciano J , Jagannath, Sundar , Baz, Rachid , Nooka, Ajay K. , Jakubowiak, Andrzej , Yee, Andrew J , Siegel, David S. , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | January 30, 2018 | Volume: 36 | Issue: 9 | Pages: 859-866

10.1200/jco.2017.75.5207 | PMID 29381435 Get It

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Tran, Nhan L. , Halperin, Rebecca F. , Phillips, Joanna J. , Kuhn, John G. , Groot, John F. de, Colman, Howard , Wen, Patrick Y. , Mellinghoff, Ingo K. , Butowski, Nicholas , Taylor, Jennie , Clarke, Jennifer , Chang, Susan M. , Molinaro, Annette M. , Maggiora, Gerald M. , Peng, Sen, Liang, Winnie S. , Trent, Jeffrey M. , Berens, Michael E. , Carpten, John D. , Craig, David W. , Prados, Michael D. , Berens, Michael E , Byron, Sara A. , Colman, Howard , Ligon, Keith L , Wen, Patrick Yung , Cloughesy, Timothy F. , Chang, Susan Marina , Berger, Mitchel S. , Molinaro, Annette M. , Nasser, Sara A. , Mellinghoff, Ingo K , Tran, Nhan L

Mayo Clinic

Clinical Cancer Research | October 26, 2017 | Volume: 24 | Issue: 2 | Pages: 295-305

10.1158/1078-0432.ccr-17-0963 | PMID 29074604 Get It

Abstract Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame following surgery for patients with recurrent glioblastoma. Experimental Design: We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. Following surgical resection, genome-wide tumor/normal exome sequencing and tumor RNA sequencing were performed to identify molecular targets for potential matched therapy. A multidisciplinary molecular tumor board issued treatment recommendations based on the genomic results, blood–brain barrier penetration of the indicated therapies, drug–drug interactions, and drug safety profiles. Feasibility of generating genomics-informed treatment recommendations within 35 days of surgery was assessed. Results: Of the 20 patients enrolled in the study, 16 patients had sufficient tumor tissue for analysis. Exome sequencing was completed for all patients, and RNA sequencing was completed for 14 patients. Treatment recommendations were provided within the study's feasibility time frame for 15 of 16 (94%) patients. Seven patients received treatment based on the tumor board recommendations. Two patients reached 12-month progression-free survival, both adhering to treatments based on the molecular profiling results. One patient remained on treatment and progression free 21 months after surgery, 3 times longer than the patient's previous time to progression. Analysis of matched nonenhancing tissue from 12 patients revealed overlapping as well as novel putatively actionable genomic alterations. Conclusions: Use of genome-wide molecular profiling is feasible and can be informative for guiding real-time, central nervous system–penetrant, genomics-informed treatment recommendations for patients with recurrent glioblastoma. Clin Cancer Res; 24(2); 295–305. ©2017 AACR. See related commentary by Wick and Kessler, p. 256
Abstract LB-007: Leveraging spatial heterogeneity in tumor purity for improved somatic variant calling of archival tumor-only samples
Halperin, Rebecca F. , Tassone, Erica E. , Adkins, Jonathan, Russell, Megan, Tran, Nhan L. , Hank, Nicole C., Newell, James, Berens, Michael, Korn, Ronald L. , Craig, David W. , Liang, Winnie S. , Newell, James, Gupta, Sandeep , Byron, Sara A. , Tran, Nhan L

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: LB-007-LB-007

10.1158/1538-7445.am2017-lb-007 Get It

Abstract Archival tumor samples present a rich resource of annotated specimens for genomics research. However, standard variant calling approaches require a matched normal sample from the same individual, which is often not available with archival tissue. Without a matched normal sample, it is very difficult to distinguish between true somatic variants and germline variants that are private to the individual. Archival FFPE sections often contain adjacent normal tissue, but this normal tissue is often contaminated with infiltrating tumor cells. Comparative somatic variant callers are designed to exclude variants present in the normal sample, so a novel approach is required to leverage sequencing of adjacent normal tissue. Here we present LumosVar 2.0, a software package designed to jointly analyze multiple samples from the same patient. The approach is based on the concept that the allelic fraction of somatic variants, but not germline variants, would be diluted by the presence of normal tissue. Given the allele specific copy number state and expected tumor fraction of each sample, one can model the expected allelic fractions of somatic and germline variants. LumosVar estimates allele specific copy number and tumor sample fractions from the data, and uses the model to call somatic and germline variants. LumosVar is also able to detect sub clonal events and spatial heterogeneity between samples. To evaluate this approach, we used a glioblastoma dataset, where enhancing (high tumor content) and non-enhancing (low tumor content) samples were available for each patient, as well as the matched normal sample to define the true somatic variants. We show that both sensitivity and positive predictive value are improved by analyzing the high tumor and low tumor jointly compared to analyzing the samples individually or in silico pooling of the two samples. Finally, we apply this approach to a set of breast and prostate archival FFPE tumor samples where normal samples were not available for germline sequencing. Citation Format: Rebecca F. Halperin, Winnie S. Liang, Erica Tassone, Jonathan Adkins, Megan Russell, Nhan Tran, Nicole Hank, James Newell, Sandeep Gupta, Michael Berens, Ronald Korn, David W. Craig, Sara A. Byron. Leveraging spatial heterogeneity in tumor purity for improved somatic variant calling of archival tumor-only samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-007. doi:10.1158/1538-7445.AM2017-LB-007
Abstract 3389: Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Hendricks, William P.D. , Kiefer, Jeffrey , Schmidt, Jessica, Sekar, Shobana , Carpten, John D. , Craig, David W. , Adkins, Jonathan, Cuyugan, Lori, Manojlovic, Zarko , Halperin, Rebecca F. , Helland, Adrienne , Legendre, Christophe, Hurley, Laurence H. , Sivaprakasam, Karthigayini , Johnson, Douglas B. , Crandall, Holly , Busam, Klaus J. , Zismann, Victoria , Lee, Jeeyun , Sosman, Jeffrey A. , Trent, Jeffrey M. , Liang, Winnie S. , Nasser, Sara A. , DeLuca, Valerie , Sekulic, Aleksander , Ariyan, Charlotte Eielson

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3389-3389

10.1158/1538-7445.am2017-3389 Get It

Abstract Genomic analyses of cutaneous melanoma (CM) have yielded biological and therapeutic insights, but understanding of non-ultraviolet (UV)-derived CMs remains limited. Deeper analysis of acral lentiginous melanoma (ALM), a rare sun-shielded melanoma subtype associated with worse survival than CM, is needed to delineate non-UV oncogenic mechanisms. We thus performed comprehensive genomic and transcriptomic analysis of 34 ALM patients. Unlike CM, somatic alterations were dominated by structural variation and absence of UV-derived mutation signatures. Only 38% of patients demonstrated driver BRAF/NRAS/NF1 mutations. Contrasting with CM, we observed PAK1 copy gains in 15% of patients, and somatic TERT translocations, copy gains, and missense and promoter mutations, or germline events, in 41% of patients. We further show that in vitro TERT inhibition has cytotoxic effects on primary ALM cells. These findings provide insight into the role of TERT in ALM tumorigenesis, and reveal preliminary evidence that TERT inhibition represents a potential therapeutic strategy in ALM. Citation Format: Winnie S. Liang, William Hendricks, Jeffrey Kiefer, Jessica Schmidt, Shobana Sekar, John Carpten, David W. Craig, Jonathan Adkins, Lori Cuyugan, Zarko Manojlovic, Rebecca F. Halperin, Adrienne Helland, Sara Nasser, Christophe Legendre, Laurence H. Hurley, Karthigayini Sivaprakasam, Douglas B. Johnson, Holly Crandall, Klaus J. Busam, Victoria Zismann, Valerie De Luca, Jeeyun Lee, Aleksandar Sekulic, Charlotte E. Ariyan, Jeffrey Sosman, Jeffrey Trent. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3389. doi:10.1158/1538-7445.AM2017-3389
Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Pierobon, Mariaelena , Ramos, Corinne, Wong, Shukmei , Hodge, K. Alex, Aldrich, Jessica, Byron, Sara A. , Anthony, Stephen P. , Robert, Nicholas J. , Northfelt, Donald W. , Jahanzeb, Mohammad , Vocila, Linda, Wulfkuhle, Julia , Gambara, Guido , Gallagher, Rosa I. , Dunetz, Bryant, Hoke, Nicholas N, Dong, Ting , Craig, David W. , Cristofanilli, Massimo , Leyland‐Jones, Brian , Liotta, Lance A. , O’Shaughnessy, Joyce , Carpten, John D. , Petricoin, Emanuel F. , Gallagher, Rosa I , Cristofanilli, Massimo

Mayo Clinic

Clinical Cancer Research | April 26, 2017 | Volume: 23 | Issue: 16 | Pages: 4919-4928

10.1158/1078-0432.ccr-16-2656 | PMID 28446508 Get It

Abstract Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K–AKT–mTOR pathway is associated with specific sites of breast cancer metastasis. Experimental Design: Next-generation sequencing–based whole-exome sequencing was coupled with reverse-phase protein microarray (RPPA) functional signaling network analysis to explore the PI3K–AKT–mTOR axis in 32 pretreated breast cancer metastases. RPPA-based signaling data were further validated in an independent cohort of 154 metastatic lesions from breast cancer and 101 unmatched primary breast tumors. The proportion of cases with PI3K–AKT–mTOR genomic alterations or signaling network activation were compared between hepatic and nonhepatic lesions. Results: PIK3CA mutation and activation of AKT (S473) and p70S6K (T389) were detected more frequently among liver metastases than nonhepatic lesions (P < 0.01, P = 0.056, and P = 0.053, respectively). However, PIK3CA mutations alone were insufficient in predicting protein activation (P = 0.32 and P = 0.19 for activated AKT and p70S6K, respectively). RPPA analysis of an independent cohort of 154 tumors confirmed the relationship between pathway activation and hepatic metastasis [AKT (S473), mTOR (S2448), and 4EBP1 (S65); P < 0.01, P = 0.02, and P = 0.01, respectively]. Similar results were also seen between liver metastases and primary breast tumors [AKT (S473) P < 0.01, mTOR (S2448) P < 0.01, 4EBP1 (S65) P = 0.01]. This signature was lost when primary tumors were compared with all metastatic sites combined. Conclusions: Breast cancer patients with liver metastasis may represent a molecularly homogenized cohort with increased incidence of PIK3CA mutations and activation of the PI3K–AKT–mTOR signaling network. Clin Cancer Res; 23(16); 4919–28. ©2017 AACR.
Abstract P1-07-09: A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
Wong, Shukmei , Reeded, A, Anthony, Stephen P. , Robert, N. J., Northfelt, DW, Jahanzeb, Mohammad , Vocila, Linda, Wulfkuhle, Julia , Dunetz, Bryant, Aldrich, Jessica, Craig, David W. , Liotta, Lucia, Carpten, John D. , Petricoin, EF, Pierobon, Mariaelena , Aldrich, Jessica, Byron, Sara A.

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 4_Supplement | Pages: P1-07-09-P1-07-09

10.1158/1538-7445.sabcs16-p1-07-09 Get It

Abstract Background: While genomic alterations are central players in tumor progression, proteins are the targets for precision therapy. The degree by which “actionable” genomic alterations translate into activated/altered proteins and pathway is still under investigation. Using a multi-OMIC approach from the SideOut 2 metastatic breast cancer (MBC) trial, this study explored the concordance between selected “actionable” genomic alterations and protein expression/activation. Methods: Snap frozen biopsies from 29 MBC patients enrolled in a prospective phase II trial were used for this analysis. Exome WES and RNASeq data was processed using an in-house developed pipeline and identified amplification of CCND1 (6/29), FGFR1 (4/29), and FGF 3, 4, 5, and 19 (4/29) as some of most frequent “actionable” genomic alterations in our MBC cohort. Signaling analysis of the 29 cases was performed using Reverse Phase Protein Microarray coupled with Laser Capture Microdissection. Protein expression/phosphorylation was measured in a continuous scale and classified based on quartile distribution. Concordance between CCND1 amplification and Cyclin D1 expression, along with the activation of FOXM1 T600 and Rb S780, was explored. Amplification of the FGFR1 locus or its ligands was correlated with the level of activation/phosphorylation of FGFR1 Y653/654. Results: While Cyclin D1 protein expression was greater than the population mean for 4/6 (67%) patients with CCND1 amplification, only 2/6 (33%) patients with CCND1 amplification had Cyclin D1 level within the top quartile of the population (n=29). FOXM1 T600 activation was independent from CCND1 amplification, with high levels of FOXM1 T600 predominantly in the CCND1 wild-type population. Only 1/6 (17%) patients with CCND1 amplification had FOXM1 T600 level similar to the top quartile of the population while a second patient was above the population median. Activation of Rb S780 was above the population median, but below the top quartile, in 2/6 (33%) CCND1 amplified patients. Similarly, none of the patients with activation of FGFR Y653/654 equal to the top quartile harbored an FGFR1 amplification. Only 1/4 (25%) patients carrying an FGFR1 amplification had an activation of FGFR Y653/654 above the population median. Similarly, 1/4 (25%) patients with FGF ligand amplification showed FGFR Y653/654 level within the top quartile while three patients had FGFR Y653/654 activation below the population median. No significant results were found between proteomic (below/above the median) and genomic characteristics by Fisher test (p>0.05). Conclusion: Molecular genotyping of “actionable” cancer targets alone may be insufficient in predicting whether the actual drug target protein is expressed and/or activated in any given patient's tumor. Although these results need further validation, the combination of genomic and proteomic data may represent a more informative approach for identifying real molecular drivers of individual lesions as well as “actionable” protein/phosphoprotein targets in the absence of genomic events. Multi-OMIC approaches may lead to more effective stratification in precision medicine trials. Citation Format: Pierobon M, Wong S, Reeded A, Anthony S, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Carpten J, Petricoin EF. A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-07-09.
A study of real-time CLIA-enabled whole genome tumor sequencing: Results for testicular cancer and sarcomatoid RCC.
Condjella, Rachel, Egan, Jan B. , Champion, Mia D., Hunt, Katherine S., McCullough, Ann E. , Kurdoglu, Ahmet, Aldrich, Jessica, Izatt, Tyler, Christoforides, Alexis, Barrett, Michael T. , Craig, David W. , Carpten, John D. , Stewart, A. Keith , Bryce, Alan H. , Borad, Mitesh J. , McWilliams, Robert R. , Nasser, Sara A. , Phillips, L Taylor , Liang, Winnie S.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 4_suppl | Pages: 463-463

10.1200/jco.2014.32.4_suppl.463 Get It

463 Background: The genomic assessment of cancer has been revolutionized by next-generation sequencing and is increasingly being applied in the clinic to guide therapeutic decision-making. Time to reporting of results, specimen quantity, and analyte quality have constrained initial clinical applications to gene panels and whole exome based strategies. Methods: Patients underwent surgical resection, excisional or core biopsies, or bone marrow biopsy. Samples were analyzed by whole genome or exome sequencing and RNA sequencing, bioinformatics analysis, and therapeutic target prioritization by a multi-disciplinary Clinical Genomics Board. All prioritized targets were CLIA validated using Sanger sequencing, RT-qPCR, FISH, or IHC as appropriate. Treatment was delivered using off-label FDA approved drugs, clinical trials, or single patient INDs. Results: We have enrolled 40 patients with advanced, treatment-refractory cancers of whom sequencing data is available on 33. The initial 6 patients were evaluated in a non-CLIA pilot phase and 27 in the CLIA enabled phase. Upon availability of the initial report, identified targets of putative therapeutic relevance were then prioritized by the CGB in 22/27 patients (81%) for subsequent CLIA validation. Eleven patients have been treated with genomically selected therapy with partial response in 3/10 assessed patients. A testicular cancer patient had aberrations in two testes specific genes, a copy number gain in TSSK6 and a novel gene fusion between thyroid hormone receptor associated protein 3 (THRAP3) and Tektin 2 (TEKT2). Additionally, a case of papillary renal cell carcinoma had an amplification of YAP1 and a previously unreported P287T mutation in CCND1, suggesting potential benefit with a CDK4/6 inhibitor. Treatment is ongoing and results will be reported. Conclusions: Integrated whole genome analysis in a CLIA setting is feasible. Integration of SNV, copy number and transcriptional data may allow for selection of putative driver genes to enhance targeted therapy decisions. Barriers for future broader implementation include the need for reduced time from biopsy to report and availability of therapies.
Impact of religious attendance on psychosocial outcomes for individuals with traumatic brain injury: A NIDILRR funded TBI Model Systems study
Philippus, Angela , Mellick, David, O’Neil-Pirozzi, Therese M. , Bergquist, Thomas F. , Bodien, Yelena G. , Dreer, Laura E. , Novack, Thomas A. , Bergquist, Thomas, Mellick, Dave , Sander, Angelle M. , Giacino, Joseph T. , Dreer, Laura E

Mayo Clinic

Brain Injury | September 13, 2016 | Volume: 30 | Issue: 13-14 | Pages: 1605-1611

10.1080/02699052.2016.1199903 | PMID 27625074 Get It

P4‐233: Small rnas in cerebrospinal fluid samples from patients with Alzheimer's disease and neurologically normal controls
Burgos, Kasandra, Beach, Thomas G. , Shill, Holly A. , Allen, Sean D. , Craig, David W. , Keuren‐Jensen, Kendall Van , Malenica, Ivana , Adler, Charles H.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2015.08.062 Get It